Hyperkalemia News and Research

RSS

Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

ProNAi Therapeutics, Inc., a leader in developing nucleic acid therapeutics, presented safety and efficacy data from its ongoing Phase II study yesterday at the 55th Annual Meeting of the American Society for Hematology (ASH) in New Orleans, Louisiana.

11 Dec 2013

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Janssen Research & Development, LLC today announced positive results from a pivotal Phase 2 global registration study (MCD2001) suggesting siltuximab, an investigational compound, along with best supportive care, exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in treating patients with the rare disorder Multicentric Castleman's Disease who are HIV-negative and human herpes virus 8-negative.

8 Dec 2013

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis will present updates on its broad cancer portfolio with more than 240 abstracts at the upcoming American Society of Hematology (ASH) annual meeting and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

4 Dec 2013

ASTRONAUT trial finds no beneficial effects of aliskiren in recently hospitalized heart failure patients

Despite high hopes that a blood pressure-lowering medication called aliskiren would help people following hospitalization for heart failure, no beneficial effects were found, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.

13 Mar 2013

Aliskiren and standard therapy not associated with reduced CV death or HF rehospitalization

Among patients hospitalized for heart failure (HF) with reduced left ventricular ejection fraction (LVEF; a measure of how well the left ventricle of the heart pumps with each contraction), initiation of the medication aliskiren in addition to standard therapy did not reduce cardiovascular death or HF rehospitalization at 6 or 12 months after discharge, according to a study published online by JAMA.

12 Mar 2013

Four-step process delivers specific, reliable clinical rules

Dutch researchers have developed a four-step strategy for formulating clinical decision support systems, which they say could help reduce “alert fatigue.”

7 Feb 2013

Dual renin angiotensin system blockade: too many cons

Any benefit of dual blockade of the renin angiotensin system is limited to its effects on surrogate endpoints, and outweighed by an excessive risk for adverse events such as hypotension, hyperkalemia, and renal failure, argue hypertension experts.

31 Jan 2013

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases.

30 Nov 2012

Eplerenone shown to reduce cumulative heart failure hospitalisations

Pfizer Inc. (NYSE: PFE) announced results from a new post-hoc analysis of the EMPHASIS-HF trial showing statistically significant reductions in rates of cumulative heart failure (HF) hospitalisations in patients with HF treated with eplerenone compared with placebo on a background of standard optimal therapy.1 The results were presented at The European Society of Cardiology Congress (ESC) in Munich.

28 Aug 2012

Caution advised with succinylcholine in critically ill

The risk for hyperkalemia after succinylcholine use for urgent tracheal intubation increases the longer patients remain in the intensive care unit, research shows.

13 Jul 2012

Researchers publish first detailed figures that show risk of Rasilez and ACE inhibitors or ARBs

Researchers at St. Michael's Hospital have published the first detailed figures showing the risk of using the prescription drug Rasilez in combination with certain other blood pressure-lowering medications.

13 Jan 2012

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis Pharmaceuticals Corporation will showcase more than one hundred and sixty presentations on data from its robust oncology portfolio at two key medical congresses this month, demonstrating significant advances for patients with cancers and hematological diseases.

3 Dec 2011

U-M Professor to review data from three prominent studies on heart failure

Roughly 5 million people in the United States live with heart failure, a condition in which the heart is unable to pump blood around the body effectively. The causes and types of heart failure vary greatly, and treatment must be tailored to each patient. In some cases, doctors will prescribe a class of diuretic drugs called aldosterone antagonists.

20 Sep 2011

New clinical data on Bristol-Myers Squibb's NULOJIX to be presented at ESOT 2011 congress

Bristol-Myers Squibb Company today announced that new data on NULOJIX (belatacept) will be presented at the European Society for Organ Transplantation (ESOT) Congress on September 4 -7, 2011 in Glasgow, Scotland, United Kingdom.

2 Sep 2011

Infants treated with certain HIV medication more likely to experience adrenal dysfunction

Infants of human immunodeficiency virus 1 (HIV-1) infected mothers who were treated before and after birth with the protease inhibitor lopinavir-ritonavir were more likely to experience adrenal dysfunction, including life-threatening adrenal insufficiency in premature infants, compared with a zidovudine-based regimen, according to a preliminary report in the July 6 issue of JAMA.

6 Jul 2011

Sorbent expands $36M Series B financing

Sorbent Therapeutics, a private biopharmaceutical company developing therapies for cardiovascular and renal disorders, announced today that it has expanded the Company's Series B financing from September 2010 by $36 million.

30 Jun 2011

Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients

Relypsa, Inc. today announced the start of dosing in a Phase 2b clinical trial of RLY5016 for the treatment of hyperkalemia in patients with diabetic nephropathy and chronic kidney disease (CKD). RLY5016 is a high capacity, non-absorbed, polymer-based potassium binder that is orally administered and has been shown to control serum potassium levels in previous studies.

28 Jun 2011

FDA approves NULOJIX

Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) approved NULOJIX, the first selective T-cell costimulation blocker indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant, in combination with basiliximab induction, mycophenolate mofetil (MMF), and corticosteroids.

18 Jun 2011

Positive results from Relypsa RLY5016 Phase 2 trial to be presented at American Society of Hypertension meeting

Relypsa, Inc. today announced the presentation of positive results from a Phase 2 clinical trial of the company's lead compound, RLY5016, a non-absorbed oral potassium binder being developed as a treatment for hyperkalemia (elevated serum potassium levels).

23 May 2011

ACE, ARB combination therapy may increase risk of kidney failure, death

Elderly patients prescribed combination angiotensin converting enzyme inhibitors and angiotensin receptor blockers had a higher risk of kidney failure and death, according to a study published in CMAJ.

22 Mar 2011